|
Market Closed -
Nasdaq
00:00:00 07/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 5.920 USD | -5.88% |
|
-6.77% | -3.74% |
| 11-05 | Myriad Genetics, Inc., Q3 2026 Earnings Call, Nov 04, 2026 | |
| 11-05 | Myriad Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
Company Valuation: Myriad Genetics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,204 | 1,176 | 1,697 | 1,248 | 573.3 | 602 | - | - |
| Change | - | -46.65% | 44.34% | -26.46% | -54.07% | 5% | - | - |
| Enterprise Value (EV) 1 | 1,864 | 1,061 | 1,595 | 1,185 | 543.6 | 553 | 534.2 | 501.3 |
| Change | - | -43.09% | 50.32% | -25.67% | -54.14% | 1.73% | -3.39% | -6.16% |
| P/E | -78.9x | -10.4x | -6.02x | -9.72x | -1.56x | -4.01x | -4.81x | -5.22x |
| PBR | 2.28x | 1.33x | 2.2x | 1.79x | 1.56x | 1.76x | 1.86x | 1.8x |
| PEG | - | -0x | -0x | 0.2x | -0x | 0.1x | 0.3x | 0.67x |
| Capitalization / Revenue | 3.19x | 1.73x | 2.25x | 1.49x | 0.7x | 0.77x | 0.73x | 0.69x |
| EV / Revenue | 2.7x | 1.56x | 2.12x | 1.42x | 0.66x | 0.71x | 0.65x | 0.58x |
| EV / EBITDA | 25.9x | -50.5x | -253x | 29.3x | 14x | -10.1x | -15x | -29.9x |
| EV / EBIT | 205x | -32.3x | -62.5x | 54.4x | 36x | -7.44x | -9.16x | -16.6x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.35 | -1.39 | -3.18 | -1.41 | -3.95 | -1.567 | -1.307 | -1.205 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 690.6 | 678.4 | 753.2 | 837.6 | 824.5 | 777.9 | 820.5 | 870.9 |
| EBITDA 1 | 71.9 | -21 | -6.3 | 40.4 | 38.9 | -54.98 | -35.73 | -16.75 |
| EBIT 1 | 9.1 | -32.8 | -25.5 | 21.8 | 15.1 | -74.3 | -58.34 | -30.26 |
| Net income 1 | -27.2 | -112 | -263.3 | -127.3 | -365.9 | -139.6 | -106.2 | -117.5 |
| Net Debt 1 | -339.8 | -114.9 | -102.4 | -62.8 | -29.7 | -48.99 | -67.76 | -100.7 |
| Reference price 2 | 27.600 | 14.510 | 19.140 | 13.710 | 6.150 | 6.290 | 6.290 | 6.290 |
| Nbr of stocks (in thousands) | 79,855 | 81,034 | 88,669 | 91,035 | 93,214 | 95,700 | - | - |
| Announcement Date | 2/24/22 A | 2/28/23 A | 2/27/24 A | 2/24/25 A | 2/23/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.01x | 0.71x | -10.06x | -.--% | 602M | |
| 37.58x | 4.41x | 16.56x | 2.28% | 197B | |
| 28.76x | 5.12x | 17.49x | 1.08% | 128B | |
| 22.7x | 3.83x | 13.73x | 2.7% | 128B | |
| 33.69x | 3.23x | 13.02x | 2.12% | 99B | |
| 18.02x | 0.21x | 13.44x | 0.7% | 64.82B | |
| 43.53x | 3.84x | 13.07x | 1.96% | 58.17B | |
| 45.13x | 11.18x | 31.39x | -.--% | 52.84B | |
| 28.95x | 7.16x | 18.29x | 1.39% | 50.69B | |
| 45.64x | 3.6x | 13.37x | 0.48% | 37.23B | |
| Average | 30.00x | 4.33x | 14.03x | 1.27% | 81.6B | |
| Weighted average by Cap. | 32.55x | 4.48x | 16.24x | 1.71% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- MYGN Stock
- Valuation Myriad Genetics, Inc.
Select your edition
All financial news and data tailored to specific country editions
